Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108,074,661
-
Total 13F shares
-
30,811,789
-
Share change
-
+1,513,135
-
Total reported value
-
$58,227,600
-
Price per share
-
$1.89
-
Number of holders
-
72
-
Value change
-
+$3,325,295
-
Number of buys
-
29
-
Number of sells
-
36
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q4 2019
As of 31 Dec 2019,
Aclaris Therapeutics, Inc. - Common Stock (ACRS) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,811,789 shares.
The largest 10 holders included
MFN Partners Management, LP, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., MORGAN STANLEY, EcoR1 Capital, LLC, Endurant Capital Management LP, Sofinnova Investments, Inc., Broadfin Capital, LLC, Rock Springs Capital Management LP, and VANGUARD GROUP INC.
This page lists
72
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.